P14.49 Prescription preferences of antiepileptic drugs in brain tumor patients: an international survey

P B van der Meer, L Dirven, M J van den Bent, M Preusser, M J B Taphoorn, R Ruda, J A F Koekkoek
2021 Neuro-Oncology  
BACKGROUND This study aimed at investigating antiepileptic drug (AED) prescription preferences in patients with brain tumor-related epilepsy (BTRE) among the European neuro-oncology community, the considerations that play a role when initiating AED treatment, the organization of care, and practices with regard to AED withdrawal. MATERIAL AND METHODS A digital survey containing 31 questions about prescription preferences of AEDs was set out among members of the European Association of
more » ... ogy (EANO). RESULTS A total of 198 respondents treating patients with BTRE participated of whom 179 completed the entire survey. Levetiracetam was the first choice in patients with BTRE for almost all respondents (90% [162/181]). Levetiracetam was considered the most effective AED in reducing seizure frequency (72% [131/181]) and having the least adverse effects (48% [87/181]). Common alternatives for levetiracetam as equivalent first choice included lacosamide (33% [59/181]), lamotrigine (22% [40/181]), and valproic acid (21% [38/181]). Most crucial factors to choose a specific AED were potential adverse effects (82% [148/181]) and interactions with other antitumor treatments (76% [137/181]). In the majority of patients neuro-oncologists were involved in the treatment of seizures (73% [132/181])). Other relevant findings were that a minority of respondents ever prescribe AEDs in brain tumor patients without epilepsy solely as prophylaxis (29% [53/181]), but a majority routinely consider complete AED withdrawal in seizure free BTRE patients after antitumor treatment (79% [141/179]). CONCLUSION Our results show that among European professionals treating patients with BTRE levetiracetam is considered the first choice AED, with the presumed highest efficacy and least adverse effects.
doi:10.1093/neuonc/noab180.162 fatcat:m3eqiu2bdvem3a6hmeqrlxusem